Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting

Journal of Internal Medicine

Volumn 251, Issue 6, 2002, Pages 518-525

  Pena R ^a   Lahoz, C ^a   Mostaza, J M ^a   Jimenez J ^b   Subirats, E ^c   Pinto X ^d   Taboada, M ^e   Lopez Pastor A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital de Puigcerda   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e Centro de Salud de Alcobendas   (Spain)

Author keywords

Apolipoprotein E; Cholesterol; Outpatient; Pravastatin; Triglycerides

Indexed keywords

APOLIPOPROTEIN E; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; FOLLOW UP; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SEX DIFFERENCE;

AMBULATORY CARE; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES; SPAIN; TRIGLYCERIDES;

EID: 0036090989     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.00991.x     Document Type: Article

References (31)

1. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: New evidence, implications and outstanding issues
2. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
3. Apolipoprotein E polymorphism and atherosclerosis
4. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study
5. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia
6. Influence of apoE polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
7. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia
8. Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients
9. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
10. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy
11. Apolipoprotein E phenotypes in familial hypercholesterolaemia: Importance for expression of disease and response to therapy
12. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipopro-teinemia: Prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin
13. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia
14. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia
15. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian Simvastatin Survival Study
16. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy
17. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner
18. Apolipoprotein E polymorphism and coronary heart disease
19. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
20. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
21. Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study
22. Modulation of plasma triglyceride levels by apoE phenotype: A meta-analysis
23. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study
24. Apolipoprotein E as a risk factor for coronary heart disease: A genetic and molecular biology approach
25. Environmental factors modulate the effect of the APOE genetic polymorphism on plasma lipid concentrations: Ecogenetic studies in a Mediterranean Spanish population
26. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world
27. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4
28. Apolipoprotein E polymorphism in men and women from a Spanish population: Allele frequencies and influence on plasma lipids and apolipoproteins
29. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study
30. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia
31. Applicability of cholesterol-lowering primary prevention trials to a general population: The Framingham Heart Study